P/E ratio for Arbutus Biopharma (ABUS)
P/E ratio as of May 2024 (TTM): -5.83
According to Arbutus Biopharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.82609. At the end of 2022 the company had a P/E ratio of -4.96.
P/E ratio history for Arbutus Biopharma from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.96 | 5.78% |
| 2021 | -4.69 | 32.02% |
| 2020 | -3.55 | 269.05% |
| 2019 | -0.9619 | -69.61% |
| 2018 | -3.17 | -2.85% |
| 2017 | -3.26 | 862.79% |
| 2016 | -0.3384 | -89.81% |
| 2015 | -3.32 | -59.45% |
| 2014 | -8.19 | -4.44% |
| 2013 | -8.57 | -472.84% |
| 2012 | 2.30 | -245.82% |
| 2011 | -1.58 | -59.86% |
| 2010 | -3.93 | -36.01% |
| 2009 | -6.14 | 560.99% |
| 2008 | -0.9285 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | -42.79% | Bahamas |
 NRC Health
NRC | 29.4 | -604.40% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.